Focus on the development of new drugs in the field of pain.

Provide non-opioid analgesics to satisfy unmet medical needs.

About Us
R&D Concept

The Company was established based on the unmet medical needs and driven by technological innovation. The Company focuses on the development of high-barrier innovative technology platforms such as long-acting injection technology, topical formulation transdermal technology, nano-delivery carrier technology, prodrug modification, and solubility enhancement technology for insoluble drugs. The Company puts a lot of emphasis on patent protection throughout the full life cycle of drug development.

The Company emphasizes a global market layout and maximize the value of the projects by launching clinical studies and product registration simultaneously in China and US. The sales scale of the series of products can be up to tens of billions RMB after they are on the market. The Company's product pipeline covers two application pathways, i.e., 505(b)(1) and 505(b)(2), with a total of nearly 10 new drug products. The Company has held a pre-NDA meeting with US FDA for its first project, QP001, and has reached several agreements.

Learn more
Therapeutic Areas

Pain is a complex physiological and psy-chological activity, and is one of the com-monest clinical symptoms. It is gaining more and more attention as the "5th vital sign" after blood pressure, respiration, pulse, and body temperature. In 2020, the International Association for the Study of Pain (IASP) revised the definition of pain to "an unpleasant sensory and emotional experience associated with, or resembling that associated with, actual or potential tissue damage".

Learn more
Sustained-release Gel Platform
XisGel®technology is suitable for improving the local duration of action of short half-life drugs...
Topical Skin Preparation Platform
ETPF®technology is suitable for im-proving the bioavailability and ease of use of topical...

Delova Biotech focuses on the unmet medical needs in the field of pain in both China and U.S. The Company has laid out nearly 10 new non-opioid analgesics, which have sequen-tially entered the clinical development stage. The Company has also applied for nearly 20 key patents.

Learn more
laid out nearly 10 new non-opioid analgesics
US pre-NDA Submitted
Domestic Clinical
  • 近日,南京清普生物科技有限公司(简称“清普生物”)再传好消息,其自主研发的首款长效术后镇痛新药QP001注射液完成了美国新药上市申请(NDA)的关键性临床研究,并成功达到主要研究终点。
  • 北京时间2022年08月18日凌晨,清普生物同FDA召开关于QP001项目的pre-NDA会议,并达成多项共识。